Barbara Sennino
Senior Vice President & Head of Early Development 3T Biosciences
Dr. Barbara Sennino is Senior Vice President and Head of Early Development at 3T Biosciences. She brings over 15 years of cancer immunotherapy experience across industry and academia, previously holding leadership roles at Turnstone Biologics, PACT Pharma, Five Prime Therapeutics, and Bavarian Nordic. Dr. Sennino earned her MSc in Biology from the University of Milan and a PhD in Biomedical Sciences from the University of Brescia, and she has authored numerous publications and patents related to T‑cell therapies.
Seminars
Join this workshop to move beyond the “AI buzzword” and confront the biological hurdles of antigen heterogeneity. As we pivot toward more complex engineering, this session addresses the critical uncertainty of target density: determining whether 20% or 80% cellular expression is the threshold for clinical success.
- Using machine learning to synthesize datasets to profile antigen prevalence across primary vs. metastatic tissues
- Identifying which novel targets are tumor-specific versus those with risky low-level expression in healthy tissues
- Deep-diving into the antigen expression level needed to trigger the action of a T-cell engager
- Developing AI algorithms that move beyond simple “positive/ negative” IHC scores to more predictive “probability of response” scores based on complex expression patterns
- Discussing how clinical trial failures can be fed back into AI models to refine the next generation of discovery
- Extracting key lessons from haematology’s shift in delivery models, including the transition from traditional IV regimens to streamlined subcutaneous approaches, and understanding how these changes have improved patient experience, clinic efficiency, and therapeutic consistency
- Leveraging haematology’s established frameworks for step‑up dosing, toxicity mitigation, and response monitoring, exploring how these principles can be adapted to solid tumor therapies to improve safety, manage CRS and related immune toxicities, and support broader outpatient administration
- Examining real‑world evidence and clinical learnings from haematology agents such as bispecifics and T‑cell engagers, and assessing how these insights are shaping the clinical deployment, exposure management, and dose optimization of emerging solid‑tumor agents, highlighting Tarlatamab and next‑generation molecules as examples of iterative improvement driving enhanced patient outcomes
- Reflecting on the move away from first generation BiTE molecules to next-generation logic-gated and multi-specific T cell engagers
- Exploring advancements in preclinical and clinical modelling of TCEs to allow for improvements in efficacy whilst minimizing system toxicity
- Evaluating the potential for TCEs to serve as a scalable, off-the-shelf alternative to personalized CAR-T therapies
